Authors
Latest:
Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable HCCPierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.
Latest:
Dr. Rao on the Rationale of the CASPAR Trial in mCRPCArpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.
Latest:
The Future of HCC TreatmentThe panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.
Latest:
Dr Barzi on the Real-World Use of Triplet Chemotherapies in mCRCAfsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.
Latest:
Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple MyelomaHans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.
Latest:
OncLive Peer Exchange on Allo-HSCT: Conclusion of DiscussionThe expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
Latest:
Dr. Ramos on the Role of BCG In Non-Muscle Invasive Bladder CancerFélix Guerrero-Ramos, MD, PhD, FEBU, discusses the role of Bacillus Calmette-Guerin in the treatment of patients with non-muscle invasive bladder cancer.
Latest:
Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian CancerLucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.
Latest:
Community-Based Programs Have the Power to Remove Clinical Trial BarriersHomogeneous trials present a missed opportunity to discover treatments that might be highly successful in a particular subset of patients.
Latest:
Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCCAnna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.
Latest:
Dr. Yeku on the Evaluation of COM701 Plus Nivolumab in Platinum-Resistant Ovarian CancerOladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.
Latest:
Novel Treatment Advances in Differentiated Thyroid CancerAn overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.
Latest:
Dr Brunner on the Heterogeneity of Relapsed Multiple MyelomaMatthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.
Latest:
CAR T-cells as Third-line and Beyond Therapy for FLBijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Latest:
Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLLChristopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.
Latest:
ESMO 2020 Highlights With Cora Sternberg, MD, FACPTROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.
Latest:
Tumor Agnostic Role of TMB Biomarker Faces ChallengesAlthough tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.
Latest:
Dr. Michot on the Examination of CC-99282 in Relapsed/Refractory NHLJean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.
Latest:
Dr. Naqash on the Results of a Tumor Profiling Study in STK11/TP53 Co-Mutated NSCLCAbdul Rafeh Naqash, MD, discusses the results of a tumor profiling study in STK11 and TP53 co-mutated non–small cell lung cancer.
Latest:
Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRCMicheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.
Latest:
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC CarePaul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.
Latest:
Dr. Simon on Ensuring Health Equity in Cancer CareMelissa A. Simon, MD, discusses ensuring health equity in cancer care.
Latest:
From Anguish to Action: Turning Despair Into Efforts to Improve Racial EquityOncology fellows at the University of North Carolina turned their despair over the murders of George Floyd and Breonna Taylor into an effort to improve racial equity.
Latest:
Dr Deng on the Evolution of the Hodgkin Lymphoma Treatment ParadigmChangchun Deng, MD, PhD, discusses the evolution of Hodgkin lymphoma management following data readouts at the 2023 ASH Annual Meeting.
Latest:
Dr. Bachanova on NK Cell Therapy in NHLVeronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.
Latest:
Dr Habib on Developments in Palliative Care For Patients With CancerM. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.
Latest:
Dr. Puri on Clinically Relevant Biomarkers in SCLCSonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer.
